header logo image


Page 481«..1020..480481482483..490500..»

What is dexamethasone? Is it effective vs COVID-19? – Philippine Star

June 26th, 2020 4:51 pm

What is dexamethasone? Is it effective vs COVID-19?

MANILA, Philippines As the world struggles to find solutions to the novel coronavirus disease 2019 (COVID-19) pandemic, an occasional dose of hope comes to break the strain of dead ends.

Recently, the World Health Organization celebrated the steroid dexamethasone for its life-saving potential for critically ill COVID-19 patients.

The next challenge is to increase production and rapidly and equitably distribute dexamethasone worldwide, focusing on where it is needed most. Demand has already surged, following the UK trial results showing dexamethasone's clear benefit. Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production, WHO Director-General Doctor Tedros Adhanom Ghebreyesus said in a Monday briefing.

This came after University of Oxford researchers found that dexamethasone reduces death in hospitalized patients with severe respiratory complications of COVID-19.

Here are your questions about dexamethasone, including its pros and cons, answered.

WHO: Dexamethasone is a corticosteroid used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects.

Dexamethasone was tested on hospitalized COVID-19 patients as part of the United Kingdoms national clinical trial RECOVERY (Randomised Evaluation of COVID-19 Therapy).

It was found to benefit critically ill patients in particular.

According to preliminary findings shared with WHO (and now available as a preprint), for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth.

WHO took care to remind global stakeholders that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm.

The local Food and Drug Administration likewise warned against misuse or unsupervised chronic use of the drug, which they said could lead to serious adverse health reactions like:

If stopped abruptly, it may cause withdrawal symptoms such as hypotension, shockand coma.

Related: FDA warns public vs non-prescribed use of steroid dexamethasone

Similar to WHO, the Department of Health has warned the Filipino public against non-prescribed use of dexamethasone, reminding that no prophylaxis (preventive treatment) or cure exists yets for COVID-19.

We strongly urge the public not to rush to the drugstores, buy this drug, and take it without the supervision of a doctor, in order to be cured or be protected from the virus... It is highly important to note that though this may be considered as a breakthrough in science, the study on this drug as a cure for COVID-19 is yet to be peer-reviewed, Health Undersecretary Maria Rosario Vergeire said last week.

Dexamethasone is yet to undergo further trials and review, but we assure the public that the DOH is in coordination with the global medical community. The department remains in close collaboration with different experts both locally and internationally in the search for a cure and other treatments that are safe and effective against COVID-19.

Related: DOH: Steroid dexamethasone no 'magic pill' vs COVID-19

The FDA also issued an advisory reminding that the unauthorized sale of dexamethasone is strictly prohibited.

There are Dexamethasone products that are currently registered with the FDA. The drug should be only dispensed by licensed establishments to patients with valid prescription. The sale of unregistered Dexamethasone or sale of the drug without valid prescription or through online platforms is strictly prohibited.

See the original post:
What is dexamethasone? Is it effective vs COVID-19? - Philippine Star

Read More...

To slow the coronavirus death toll we may need to slow down ageing – Wired.co.uk

June 26th, 2020 4:51 pm

Marco Bertorello via Getty Images

In March, as Vadim Gladyshev shifted through the reams of data detailing the kinds of people who were more likely to fall victim to Covid-19, the Harvard biochemist started to wonder if we were thinking about the viral infection in the wrong way.

In Europe, 95 per cent of those killed by the disease were aged 60 or over. According to the UN, the fatality rate for those over 80 is five times the global average. Although many infectious diseases impact older people disproportionately, with Covid-19 the skew towards older people is devastating. Given all this, Gladyshev wondered, why arent we treating Covid-19 as a disease of ageing?

As he watched the global arms race to try and find a treatment which either neutralised the SARS-CoV-2 virus or dampen the overactive immune response which leads to many of the deaths, Gladyshev one of the worlds leading experts on the causes of ageing could not help but ponder if academics and pharmaceutical companies across the world were heading down the wrong path. If Covid-19 has the greatest impact on the elderly, rather than targeting the virus, should we not be focusing more on strengthening the host? he says.

Since the 1930s, scientists have sought clues on how to turn back the ageing process in humans by first trying to extend lifespan in rodents, with two drugs rapamycin and metformin showing signs of promise. While it is doubtful that these drugs would be useful in severe cases of Covid-19 where patients are already on ventilator support, Gladyshevs idea was simple. Could prescribing these drugs to the elderly as preventative measures could give the most vulnerable a better chance of fighting off Covid-19, and prevent them getting to that stage?

Since April, his idea has been taken up by a series of scientists across the US ranging from pharmacologists at Thomas Jefferson University to the Boston-based biotech company resTORbio, who are now testing forms of rapamycin in a series of clinical trials over the coming months.

While rapamycin and metformin are typically known for their clinical uses in cancer and diabetes respectively, the reason why Gladyshev and other longevity scientists think that these drugs could protect the elderly from covid-19 is linked to theories regarding biological age. We typically measure age chronologically based on the number of years a person has been alive, but there is a school of thought that biological age determined by biomarkers varying from DNA expression to the length of telomeres, the tips of chromosomes can vary depending on factors ranging from lifestyle to genetics.

Nir Barzilai, founder of the Institute of Ageing Research at the Einstein College of Medicine in New York, argues that the reason some people are less prone to age-related diseases such as cardiovascular disease, dementia, cancer and infections, is because their biological age is much younger. By the age of 65, half of people in Europe have two diseases or more, but half have less, says Barzilai. For me, this is due to their differing biological ages.

Most of the evidence that drugs might be able to reverse some of the hallmarks of ageing, and thus make an elderly person more resilient to viral infections, comes from studies either in human cells or rodents. This data suggests that rapamycin has the potential to revitalise the bodys natural defence mechanisms within the lungs, stimulating cells such as macrophages which are designed to seek out and remove viruses to work more efficiently.

But there have also been further findings in humans which has given longevity researchers increased confidence that they are on the right lines. Back in March, doctors in Wuhan published a study showing that diabetics taking metformin were much less likely to die of Covid-19 than diabetics not on the drug, an interesting finding which backed up previous epidemiological data showing that it can improve lifespan in diabetics. An earlier clinical trial conducted by resTORbio, using a formulation of rapamycin called RTB101, reported that it could reduce rates of respiratory viral infections in healthy people over 65.

Nevertheless when the Covid-19 pandemic began, few specialists outside of longevity research were aware of the anti-ageing properties of these drugs. At the start of April, Edwin Lam a pharmacology researcher at Thomas Jefferson University was looking at a study from molecular biologists across the US which used computer models to predict which drugs performed best when it came to helping the body remove the virus. To his surprise, rapamycin and metformin ranked top, ahead of many highly touted alternatives such as hydroxychloroquine.

Initially I thought this seemed far-fetched, says Lam. But then I looked further and found that some scientists had previously used a form of rapamycin called Sirolimus to treat people with severe cases of H1N1 bird flu. They saw a reduction in the viral load and better clinical outcomes. It had also shown antiviral activity in a preclinical model of Middle East Respiratory Syndrome. I presented this to my colleagues and we became really intrigued.

Lam has now designed a placebo-controlled clinical trial to see whether rapamycin can reduce the viral load in 20 patients with mild to moderate cases of Covid-19. A similar study is also taking place at the University of Cincinnati. ResTORbio are now looking at whether giving 550 nursing home residents an oral capsule of RTB101 each day over a period of one month, could protect them from becoming severely infected with the virus, and needing hospitalisation.

Nursing home residents have a very high risk of dying from Covid-19, says Joan Mannick, co-founder and chief medical officer of resTORbio. This elevated mortality has made the public acutely aware of the dysfunction of the aging immune system. I think the pandemic has the potential to catalyse interest in therapeutics that target aging biology as a new way to improve the function of aging organ systems.

But other scientists looking at ways to protect the elderly from Covid-19 caution that while they will be monitoring the results of the trials with interest, the evidence regarding the effectiveness of anti-ageing drugs remains limited. Its an interesting approach, but the data will have to speak for itself, says Ofer Levy, who heads the Precision Vaccines Program at Boston Childrens Hospital. Its all about safety and efficacy. Is it safe, how long can they be on it, and then is it effective? But its something to consider.

Levy points to another potentially promising approach for protecting the elderly from Covid-19, vaccines which are specifically designed for older people. These typically contain additional chemicals known as adjuvants to try and kick-start the ageing immune system. Its an approach which was successfully used by British pharma company GlaxoSmithKline to create the Shingrix vaccine in the past five years. This has shown to be highly effective in preventing shingles in people over 50, and Levy is looking to apply this strategy to a Covid-19 vaccine.

One of the ironies of vaccine development is that while over 65s stand to benefit most from immunisation, research has often shown that vaccines against influenza and other infections are at their least effective in the very old. This is thought to be due to changes in the blood which affect the immune response. As we age, the blood plasma changes and we tend to develop a low level of inflammation in our bloodstream, Levy says. Because of this, when you try to immunise someone, you often get an incomplete response to the vaccine.

Instead, Levys group is designing a vaccine which is specifically modelled on older immune systems. Our approach is to take blood donations from elderly volunteers, and then we isolate the immune cells in a dish, he says. We then screen lots of small molecules until we find ones which are like rocket fuel to the immune system, we add them to the vaccine and select the formulations which seem to work best against the coronavirus. This is completely different to normal vaccine development as were actually designing it with the ageing immune system in mind.

He hopes that such a vaccine could be in clinical trials by autumn 2021. Barzilai points out that in the meantime there is some evidence to suggest that supplementary treatment with rapamycin could enhance the effectiveness of the first wave of vaccines when they become available, with Japanese company AnGes hoping to make their Covid-19 vaccine available at the start of next year. Rapamycin has previously been shown to enhance the effectiveness of the influenza vaccine. Im sure that the initial vaccines will not be effective in the elderly, because their designs ignore their immune deficiencies, Barzilai says. But rapamycin could make a difference.

With the increased interest in rapamycin, longevity scientists predict that Covid-19 could prove to be a major boon for the field of anti-ageing research, a sector which has already been benefiting from injections of funding in recent years. Last year Barzilai received $75 million (60.5m) to conduct the TAME clinical trial, looking at whether giving metformin to elderly people over a period of four to five years can give them more years of good health. Gladyshev says that the three Covid-19 clinical trials involving rapamycin could provide a whole host of information regarding its ability to reduce biological age.

However, Barzilai is still frustrated that many within the medical community appear to be unaware of the potential of these drugs. He points to the Wuhan study in March, saying that while similar findings have been observed in Italy and Spain, no one has conducted a clinical trial looking at whether administering metformin to the elderly population in general, can offer protective benefits against Covid-19.

The major problem is that our health organisations are in silo and so ageing is often overlooked as a risk factor in these diseases, he says. For me, the question is why are we not using these two drugs on a wider scale to try and protect the vulnerable, when we already have information that they can offer benefit? Metformin has been used clinically for 60 years, its already known to be safe. If we just focus on stopping the disease in older people, the whole mortality issue would be different, the lockdowns wouldnt need to happen, and the economic impacts would be less as well.

Google got rich from your data. DuckDuckGo is fighting back

The Animal Crossing fans running in-game businesses

Inside the 'bullshit' get-rich-quick world of dropshipping

The secret behind the success of Apple's AirPods

The UK's lockdown rules, explained

Follow WIRED on Twitter, Instagram, Facebook and LinkedIn

Get The Email from WIRED, your no-nonsense briefing on all the biggest stories in technology, business and science. In your inbox every weekday at 12pm sharp.

by entering your email address, you agree to our privacy policy

Thank You. You have successfully subscribed to our newsletter. You will hear from us shortly.

Sorry, you have entered an invalid email. Please refresh and try again.

Read more:
To slow the coronavirus death toll we may need to slow down ageing - Wired.co.uk

Read More...

13 diaper rash creams that *really* work – Motherly Inc.

June 26th, 2020 4:51 pm

Although diaper rash is never something you want to deal with, odds are you've probably fought the good fight with this red, irritating and super common baby and toddler skin ailment more than once during your time as a mama.

Almost every baby suffers through diaper rash at some point during their first few years of life. Prolonged wetness, friction and sensitive baby skin combine into a recipe for disaster when it comes to baby bums and, although generally harmless, diaper rash can be pretty painful and irritating for those little tushes.

Enter diaper cream: A mama's best friend for treatment and prevention of diaper rash, and a staple on the changing table and in every diaper bag.

But with so many to choose from, you need to know which diaper creams actually get the job done. (Because let's be real, you're already spending enough time trying to wrangle your little one for a diaper change in the first place!)

A longstanding favorite among moms, Triple Paste medicated ointment delivers the double whammy of not only healing diaper rash quickly (seriously, mamas, this stuff is magic) but preventing it, as well. It's fragrance-free and hypoallergenic. Plus, a little goes a long way, which means one tub will last for quite a while.

We love a product that can multitask. This ultra-gentle, 100% natural olive oil based gel-to-cream balm not only prevents and knocks out diaper rash, it also works as a nipple balm, cradle cap treatment, lip balm and to soothe eczema. The non-greasy, fragrance-free formula is perfect for even the most sensitive skin of newborns through adults.

Aquaphor is the stuff of dreamsfrom chapped lips to minor cuts + scrapes, there's hardly anything that this magical ointment can't help with. And diaper rash is no exception!

Aquaphor protects baby's skin from wetness, acidity and chafing, and unlike petroleum jelly, creates a barrier over the skin which heals while still enabling the flow of water and air. Added bonusit also works great on mama's dry hands!

Made with 100% natural ingredients from Mongolia, this rich and creamy balm melts right in to protect and soothe baby bums, rolls and creases. The main ingredient, tallow, has been used for centuries by nomadic herders across their harsh climate is ethically and sustainably sourced and provides an unparalleled barrier against moisture and irritation. Bonus: After washing hands a million times a day, this is the only thing that helped my super chapped hands.

How can we not love a diaper rash cream with the slogan "let's kick some rash?" Developed by a pharmacist with four kids who wasn't satisfied with any of the diaper rash creams on the market, Boudreaux's is effective and is made without any harsh chemicals, which is a major win in our book.

This rich and creamy formula might be the most luxurious diaper cream we've ever slathered on a baby bum. It's packed with 18 natural and organic ingredients which have all been carefully selected to nourish and calm irritation. Calendua and chamomile help soothe while things like zinc and shea butter protect against moisture. A little goes a long way!

Desitin takes a spot on our best-of list because it contains the maximum level of zinc oxide available without a prescription, making it a top choice for serious diaper rash. It's thick and rich, creating a strong protective barrier between your baby's diaper and her sensitive skin. It also acts as an anti-inflammatory, reducing the redness and pain that goes along with diaper rash.

This calming salve uses calendulaa flower used to treat inflammation and painto soothe baby bottoms and treat and prevent diaper rash. Infused with other herbs like tea tree oil and shea butter, we love it as one of the more natural diaper rash creams on the market.

Cetaphil is one of our faves for our own skin, so using it on our little ones' sensitive bottoms is a no-brainer. The soothing cream is filled with vitamins and other organic ingredients, and the fresh scent isn't overpowering.

Honest Company is about more than just adorable diapers. Made without phthalates, parabens, fragrances, dyes and other potentially harmful ingredients, this quick-acting diaper rash cream uses zinc oxide and other organic ingredients to relieve even the most stubborn of rashes. It also helps moisturize those tiny bottoms + is easy to apply.

Like a few of our other picks, this European brand also features calendula, along with other natural extracts and oils, to combat diaper rash. Because of its natural makeup, we've found this diaper rash cream to be especially effective for babies with super sensitive skin.

assets.rebelmouse.io

A+D stands the test of time as one of the best diaper rash creams around. The soothing ointment easily glides onto skin, so it's great to apply on-the-regular for continuous protection against a diaper rash.

Maker of some of our favorite baby skin care products around, California Baby has been known for over 20 years as a go-to for safe, natural, and effective products for babies and kids with sensitive skin. This preservative-free, fragrance-free and super concentrated cream uses zinc oxide and other natural ingredients to treat and prevent diaper rash. It's also safe to use with cloth diapers.

We independently select and share the products we loveand may receive a commission if you choose to buy. You've got this.

The rest is here:
13 diaper rash creams that *really* work - Motherly Inc.

Read More...

Covid Organics: Malagasy potion and patronising West – Daily Sun

June 26th, 2020 4:51 pm

Adebisi Tijani

Throughout ages and millennia, human societies across the world have always had well-established indigenous healthcare systems that helped sustain life and their respective civilisations.

It is, therefore, clear that no culture nor nation on earth has any monopoly over or exclusive rights to the application of pharmacology for the effective treatment of diseases. This draws from the fact that pharmacology has been a common therapeutic art of every culture on earth before the modern scientific wave of pharmaceutics.

It was, therefore, heartwarming news for Africa when Madagascar announced a locally manufactured drug for the cure of the coronavirus pandemic sweeping the world.

Madagascar, quarantined around 400 kilometres off the East African country of Mozambique, instantly leapt out of obscurity.

The medical feat came through as a result of a collaboration between the Malagasy Institute of Applied Research (MIRA) and the National Pharmacology Research Centre.

The herbal medicinal potion or drink, known as COVID ORGANICS (CVO), has since been stirring predictable controversies between herbal medicine and big pharma drugs and outright racists that would never see anything good from Africa.

But the Malagasy President, Andry Rajoeiina, would not be browbeaten. He endorsed and launched the herbal drug for the treatment of COVID-19 patients. According to Rajoeiina, the thrust of promoting the locally-made herbal drug is not only to help save lives in his country and the world, but to also help raise funds that will be re-invested in more advanced medical and sundry scientific pursuits at the Malagasy Institute of Applied Research.

Africanews, quoted the President as saying: All trials and tests have been conducted and its effectiveness has been proven in the reduction and elimination of symptoms of the COVID-19 patients in Madagascar.

Herbal medicine, in pulverized or liquid form, known as agbo across West Africa, is a common indigenous medicine among Black people in Africa. It has been used for both curative and preventative purposes since time immemorial.

But the World Health Organization (WHO) did not join the Halleluyah chorus for the indigenous Malagasy medical breakthrough. In its initial reactions, WHO officially declared that it had not recommended the drug as a cure for COVID-19, and, as such, warned against its prescription for the treatment of the disease. Upon such stance,the WHO tagged the nationally recommended use of Covid Organics as being tantamount to self-medication, as against medication by scientific prescription.

But Africans have roundly ignored the WHO on this, particularly since there is yet no known cure for the disease. Moreover, the Malagasy President had declared that the medication would be given away for free to the most vulnerable but sold at very low and affordable prices to those outside such bracket. He backed it up, deploying soldiers for door-to-door free distribution of Covid Organics.

In Antananarivo, the capital of Madagascar, pharmacies and supermarkets are said to be stocking up their shelves with CVO. And its been widely reported that no sooner were the drugs displayed than they disappeared from the shelves as a result of the relatively insatiable demand.

Experts at the Academy of Medicine of Madagascar have reassured residents of the island nation that it has duly established the medicinal properties of the herbal drug. But then, for thorough scientific self-assessment, the academy has put up a monitoring system to appraise the efficacy of the medicine across the various demographic spheres of its consumption. It equally explained that it was not putting up Covid Organics as an exclusive cure for COVID -19 and, therefore, upheld the individuals discretionary choices. It also urged users to strictly comply with the recommended dosage.

According to local media reports, Rakoto Fanomezantsoa, a military doctor and director-general of Suavinandriana Hospital, has shed further light on Covid Organics. The doctor explained that one of the medicinal qualities of CVO is that it not only strengthens the immune system, it helps eliminate viruses as well.

Among the early African leaders to endorse the innovative indigenous medicine were the heads of state of Guinea Bissau, Senegal, Cameroon, Comoros and Tanzania.

The miracle plant behind the global appeal of Covid Organics is known by the scientific name Artemesia annua, otherwise referred to as sweet wormwood, which belongs to the daisy family. Clinical studies carried out in Western laboratories, in efforts to ascertain the vaunted curative powers of Artemesia annua, have been rated as both interesting and promising.

The plant was introduced to Madagascar from Asia in the 1970s for the treatment of malaria, and forms the base of the popular drug, artemisinin.

Following a heated outcry across Africa against the WHO over the drug, it has since modified its stance. Matshidiso Moesi, WHOs regional director for Africa, in a recent media briefing, declared: We are advising the government of Madagascar to take this product through a clinical trial and we are prepared to collaborate with them.

Last month, visiting President of Guinea Bissau, Vinaro Sisoko Embalo, presented to the Nigerian head of state, President Muhamadu Buhari, a sample of Covid Organics as a gift from President Rajoeiina.

Upon praising the medical innovation from a fellow African country, Buhari called for its validation by Nigerias medical establishment.

Africa keeps on working out indigenous ways of solving her numerous problems without worrying much about Western bias. Whereas a kit for private testing of coronavirus is sold for 250 in London, Senegalese medical scientists have come up with an equally effective kit for an incredible price of $1.

Writing in The Guardian of London, Afua Hirsch noted: The African continent has a stellar way of innovating its way out of problems just look at how mobile money and fintech has turned it into one the most digitally savvy regions of the world.

It has been well documented how a patronising attitude towards East Asia is what allowed European countries to be caught by such surprise at the spread of this (coronavirus) disease. Now a similar mindset seems to ensure we dont learn the lessons Africa has to offer in overcoming it.

On French television, President Andry Rajoeiina of Madagascar put across a poser: If it was a European country that had actually discovered this (Covid Organics) remedy, would there be so much doubt?

He did not wait for a response.

And, on behalf of Africa, he declared: CERTAINLY NOT!

";n.innerHTML="window._taboola = window._taboola || [];_taboola.push({mode:'thumbnails-c', container:'taboola-below-article', placement:'below-article', target_type: 'mix'});window._taboola = window._taboola || [];_taboola.push({mode:'thumbnails-d', container:'taboola-below-article-second', placement:'below-article-2nd', target_type: 'mix'});";insertAfter(t,e);insertAfter(n,t)}injectWidgetByMarker('tbmarker');

Follow this link:
Covid Organics: Malagasy potion and patronising West - Daily Sun

Read More...

Coronavirus’s Genetics Not Changing Much, And That Bodes Well For A Vaccine : Shots – Health News – NPR

June 26th, 2020 4:50 pm

Internationally, scientists now have on file the genomes of more than 47,000 different samples of the virus that causes COVID-19 up from just one in January. Here's a transmission electron micrograph of SARS-CoV-2 virus particles (orange) isolated from a patient. National Institute of Allergy and Infectious Diseases/National Institutes of Health hide caption

Internationally, scientists now have on file the genomes of more than 47,000 different samples of the virus that causes COVID-19 up from just one in January. Here's a transmission electron micrograph of SARS-CoV-2 virus particles (orange) isolated from a patient.

Scientists are monitoring the virus that causes COVID-19 for genetic changes that could make a vaccine ineffective. But so far, they're not seeing any.

"There's nothing alarming about the way the coronavirus is mutating or the speed at which it's mutating," says Emma Hodcroft, a molecular epidemiologist at the University of Basel in Switzerland. "We don't think this will be a problem [for vaccines] in the short term."

"To date, there have been very few mutations observed," says Peter Thielen, a senior scientist at Johns Hopkins Applied Physics Laboratory. "And any mutations that we do see are likely not having an effect on the function of the virus itself."

That's good news for scientists working to produce an effective vaccine by the end of the year. And it reflects the enormous quantity of genetic information on SARS-CoV-2, the virus that causes COVID-19, that researchers have amassed since the virus appeared in China late last year.

In January, scientists were limited to just one whole genome sequence of the virus. "Today we have over 47,000 coronavirus genomes that have been submitted to international databases," Thielen says.

New genomes are added every day by teams of scientists from around the world. And each time a new one arrives, it gets a close examination, Thielen says.

"What we're looking for in the data is similarity between the virus that first emerged and the genome that had been deposited and any changes that have occurred in the virus," he says. And overall, the viruses circulating today look remarkably similar to the ones first identified in China.

There had been concern about mutations because SARS-CoV-2 is a type of virus capable of quickly changing its genes. But unlike many similar viruses, the coronavirus uses a proofreading system to catch any errors in the genetic code when it begins generating copies of itself.

"The targets for vaccine design today remain the same as we would have designed them in January."

Peter Thielen, Johns Hopkins Applied Physics Laboratory

"So if there's a change, it will actually make a correction at a specific location," Thielen says.

Vaccine developers have been especially concerned about genetic locations that affect something called a spike protein. It's a structure on the surface of the coronavirus that allows it to invade cells.

Spike proteins also give the virus its distinctive appearance and account for its name. Scientists who first viewed a coronavirus through an electron microscope were reminded of the solar corona.

The candidates for a coronavirus vaccine now under development are all designed to teach the immune system to recognize these spike proteins. So far, Thielen says, that's looking like a good strategy.

"The targets for vaccine design today remain the same as we would have designed them in January," he says.

Some other well-known viruses have proved less amenable to the strategy of using the same vaccine from year to year. Influenza, for example, is constantly altering its surface proteins in ways that require annual vaccine updates for each strain that's making the rounds that year.

"Flu just really loves to change these parts," Hodcroft says. "And that's why we can end up with such different flus from season to season."

Measles represents a virus at the other extreme its genome has stayed fairly consistent over the years, at least in the ways that trigger immunity in people after infection. That means children today still get a measles vaccine that was developed in the 1960s, and it provides immunity for a lifetime.

Hodcroft says she thinks SARS-CoV-2 is likely to fall somewhere between the flu and measles when it comes to making a vaccine.

"I think in the short term we'll find something," she says. "The big question is whether this is something we'll be able to vaccinate once and then you never have to get it again, or will it be something you'll have to get every couple of years to keep your immunity up to date."

Scientists are uncertain because the coronavirus is still so new, Hodcroft says.

"We haven't really seen the full diversity of how the virus can mutate," she says. "It gathers mutations over time. We can't speed up time, so we just have to wait and see."

At the moment, though, vaccine developers have more pressing concerns than mutations. First, they'll have to demonstrate that they can produce vaccines that are both safe and effective. Then they'll have to make huge quantities.

"It's not a small feat to manufacture a vaccine for billions of people and then to get it to all of those people," Hodcroft says.

That will take months, she says, in addition to the months required to develop a vaccine in the first place.

See original here:
Coronavirus's Genetics Not Changing Much, And That Bodes Well For A Vaccine : Shots - Health News - NPR

Read More...

New Genetic Mutations Linked to ASD – Technology Networks

June 26th, 2020 4:50 pm

Scientists at Sanford Burnham Prebys Medical Discovery Institute and Radboud University Medical Center in the Netherlands have identified mutations in a gene called CNOT1 that affect brain development and impair memory and learning. The study is the first to link neurodevelopmental delays with CNOT1, suggesting that drugs that help restore the genes function may have therapeutic benefit. The research, published in The American Journal of Human Genetics, also revealed that CNOT1 interacts with several known autism spectrum disorder (ASD) genes, opening new research avenues for the condition.Prior to this work, the CNOT1 gene was not on the radar of autism researchers, says Rolf Bodmer, Ph.D., director and professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys and the studys co-corresponding and co-senior author. This discovery could help us better understand the genetic mechanisms underlying ASD. Our work is also a first step toward exploring drugs that could augment the function of CNOT1 and might be able to help children with neurodevelopmental delays who have these specific mutations.

The cause of developmental disabilities, including ASD, is poorly understood. Research indicates that there may be a genetic component to these conditions, but the precise impact of the genetic variations that have been uncovered to date is unclear. Identifying the underlying cause of developmental disabilities would allow scientists to create diagnostic tests that would provide early diagnoses and potential treatments.

To answer this question, the researchers at Radboud University turned to Bodmer, a world-renowned genetics expert who studies how genes contribute to disease using a fruit fly model. Sreehari Kalvakuri, Ph.D., a postdoctoral researcher in the Bodmer lab, created fruit flies that contained the same CNOT1 variations seen in the patients, including DNA sequences that were misspelled (missense), cut short (truncated) or otherwise altered.

This work identified nine CNOT1 variants that impaired learning and memory, which was measured by several independent approaches including a courtship assay that tested the ability of male fruit flies to remember if their female partners had paired with other males. All of these variants appeared spontaneously (de novo) in the patients, meaning they were not inherited. The scientists also discovered that these CNOT1 mutations interact with known ASD genes revealing a genetic link to ASD that can be further explored.

Fruit flies are a great biological model because we can complete genetic studies very quickly. This work only took a few months instead of the potential decade using a mouse model, says Kalvakuri, the studys co-first author. Additionally, the CNOT1 gene is highly conserved between fruit flies and humans, meaning it does not change much, so we are optimistic these findings can be extrapolated to people.

Next, the scientists plan to identify which molecular components interact with CNOT1, which functions as a scaffold that builds up a larger protein complex. This work might uncover additional potential drug targets for intellectual, learning or memory disorders, including ASD.

The first step toward helping children with neurodevelopmental delays is to determine the cause of the condition, says Bodmer. Our ultimate hope is to find a treatment that could be given as early as possible to help these children stay on track developmentally.

Surprisingly, the findings also have implications for heart disease, the primary focus of Bodmers lab.

A significant fraction of these patients also have cardiac defects, says Bodmer. Conversely, children who are born with heart defects are at a higher risk of developing ASD, too. This study on CNOT1 also provides a previously unknown genetic link between heart function and ASD.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Excerpt from:
New Genetic Mutations Linked to ASD - Technology Networks

Read More...

Should you travel this summer? Heres a guide to vacation amid the coronavirus pandemic. – Peoria Journal Star

June 26th, 2020 4:50 pm

To some, the idea of taking a summer vacation amid the COVID-19 pandemic is out of the question. With COVID-19 cases reported in all 50 states, the Centers for Disease Control and Prevention recommends people stay home to protect themselves and others from getting sick.

"COVID-19 remains an ongoing pandemic with sustained community transition even if you are traveling to a place with fewer cases," said Dr. Benjamin Singer, assistant professor of medicine (pulmonary and critical care) and biochemistry and molecular genetics at the Northwestern University Feinberg School of Medicine.

To others, a carefully distanced excursion to the woods or a secluded beach is in the works after months of staying close to home.

"There will be lots of people who take trips, come home and everything is fine. But there are going to be other people who take trips and end up sick who wouldnt have otherwise gotten sick if theyd stayed home," said Dr. Emily Landon, associate professor of medicine, infectious diseases expert and epidemiologist at University of Chicago Medicine. "Its really up to you, about what you want to spend your personal risk on."

For those planning a trip away from home this summer, the Tribune asked medical experts what precautions and items to take on every step of a journey by airplane, car or train. What follows are their answers, along with guidance from the CDC, Transportation Security Administration, and other state and federal agencies.

Whatever your plans, dont lose sight of this opportunity to enjoy quality time with those youve been hunkering down with since March. "2020 may not be the summer we thought we would have, but find time to read, explore and find the joy around you and savor what you can," said Dr. Amy Bohnert, associate professor of clinical and developmental psychology at Loyola University Chicago, "That is a gift we can give our kids that will last a lifetime."

BEFORE YOU GO

Q: First off, is travel safe?

CDC: Travel increases your chances of getting and spreading COVID-19. We dont know if one type of travel is safer than others; however, airports, bus stations, train stations and rest stops are all places travelers can be exposed to the virus in the air and on surfaces.

Q: What factors should go into picking a destination?

CDC: The following should be considered when thinking about planning a trip away from home:

Is COVID-19 spreading in your community? Even if you dont have symptoms, you can spread COVID-19 to others while traveling.

Is COVID-19 spreading at your destination? You can get infected while traveling. You can also spread the coronavirus without symptoms to loved ones when you return.

Would you have to quarantine for 14 days after arriving at your destination? Check the state and local requirements.

Q: Are there any groups of people for whom you would not recommend travel for this summer due to the coronavirus pandemic?

Singer: "Higher-risk groups, including older adults and people with chronic health conditions."

Q: Is one form of travel safer or limits exposure to COVID-19 better than others?

Singer: "Staying at home is the safest option, but travel options that allow you to stay socially distant would be considered the safest."

Dr. Erica Hartmann, assistant professor of environmental engineering at Northwestern University: "I personally would opt for modes of transportation that are less densely crowded and allow for lots of ventilation."

TAKING A ROAD TRIP

Q: What is the general guidance?

CDC: Making stops along the way for gas, food or bathroom breaks can put you and your traveling companions in close contact with other people and surfaces. You may have to stop less often, but RV travel typically means staying at RV parks overnight and getting gas and supplies at other public places. These stops may put you and those with you in the RV in close contact with others. One approach for eating is to pick up food at drive-thrus or curbside restaurant service.

Q: Its inevitable Ill need to stop and use the restroom during my trip. Is there any way to prevent germs from following me back to my car?

Hartmann: "Wash your hands. Which really, you should be doing regardless of COVID-19.

"Perhaps not directly related to your question, but remember to practice social distancing in the restroom if there are multiple people in the restroom. And maybe you shouldnt talk while youre in there."

GOING BY AIR?

Q: What is the general guidance?

CDC: Air travel requires spending time in security lines and airport terminals, which can bring you in close contact with other people and frequently touched surfaces. Most viruses and other germs do not spread easily on flights because of how air circulates and is filtered on airplanes. Social distancing, however, is difficult on crowded flights, and you may have to sit near others (within 6 feet), sometimes for hours. This may increase your risk for exposure to the virus that causes COVID-19. Wear a nonmedical, fabric face covering during the flight.

AT THE AIRPORT

Q: A trip to the airport is in my future and Im worried about potential COVID-19 exposure. How can I protect myself in the terminal?

Landon: "My moms 75 years old. Shes been stuck in Florida much longer than usual because of the pandemic, but its time to come home. Shes traveling in a week and a half. Weve had a lot of discussions about what to do. Heres what I would do if I was going to fly right now, and this is what I advised my mom to do, as well.

"When you get in the security line, then try to keep distance from the people around you. Make sure you are wearing your mask, if you can, then manipulate the situation so youre in line with other people wearing their masks. If the person in line in front of you doesnt have a mask on, then let other people go ahead. Security will touch your stuff. Dont freak out about it. Hopefully, they will be wearing masks, too, because thats required and recommended. When you get your stuff back from security what you should do every single time is wash your hands. If you dont have time to stop and wash your hands in the bathroom, then use your hand sanitizer.

"After security, get some space and keep some space between yourself and other people before you have to board your flight. You dont want to be stuck sitting close to other people. Maybe that means finding an empty gate or one that doesnt have a flight going out right now where you can sit at instead. Theres no rule that says you have to sit at your crowded gate before your flight. When its time to line up to board the flight, try to keep some space. Just remember the CDC doesnt count an exposure unless youre within 6 feet of someone for 15 minutes or more. Just wait to get up and only get in line when its your turn. The person standing behind you is going to do what they want to do, and theres not much you can do about it."

ON THE PLANE

Q: I know I will need a face covering. What type would you suggest for the flight?

Landon: "Youll want to bring a really high-quality fabric mask or a medical mask for traveling. You need to make sure your mask is super protective not just preventive. Fabric masks are great for holding in your own respiratory droplets. But if other people arent wearing their masks, then they are not holding in their respiratory droplets. If everyone wears a preventive mask, then, together, everything is safer all around. But if you cant count on other people to do that, then you need to have a really good fabric mask like the World Health Organization recommends. Probably two or three layers with a high thread-count cotton and/or silk inside of it or a filter pocket inside of it. One that fits you well. Thats what I would wear. I find fabric masks to be a lot more comfortable than medical masks.

"I would try not to take off my mask during the flight you may need to in order to have a drink of water on a 4-hour flight. But on a short flight, you could probably get away with drinking before you board and then drinking again when you get off the plane."

Q: What should I do when I arrive at my seat?

Landon: "I would wipe down the armrest and the tray table. If Im in the window seat, then I would wipe that down, too, because thats what people often lean against and put their hands on. Then I would sit in my seat, wash my hands again with hand sanitizer and sit tight. Leave your mask on for the flight.

"Youre really only at risk from the people within a couple of seats of you in any direction. So, two seats behind you, two seats diagonally, two seats in front of you. Thats what youre really worried about.

"If someone is coughing in the back of the plane, then dont freak out. People passing you in the aisle, dont freak out. Theoretically, the window seat is the safest."

Q: I see people sitting near me who have taken off their mask during the flight. What should I do?

Landon: "When we think about how to protect people out in the world from COVID-19, I like to describe it as a layered or stacked approach. We stack up interventions. None is meant to be perfect on its own. You can rely on cleaning your hands, wiping down your seat, keeping your distance from other people these are all ways to reduce your risk when traveling. But some of them arent as easy to do when traveling, like protecting your eyes. So, if other people are coughing or sneezing or have respiratory droplets that are contagious, then that can get in through your eyes. A mask doesnt protect them. And your regular glasses arent great protection either.

If you find yourself stuck on an airplane with someone two rows behind you or one seat behind you coughing or, say, the guy next to you doesnt look all that well you want to be able to add an extra layer of protection.

Dr. Emily Landon, University of Chicago Medicine:

"I strongly recommend bringing one of these plastic face shields that covers your mask. It will help protect your face, your eyes and mask from becoming contaminated. They are really comfortable. The first time you put one on, youre like, This is ridiculous, but you can see your whole face through it. You can wear your mask underneath it. In fact, were recommending them for little kids at school, when schools go back, that they might be a better form of protection than trying to get them to keep their masks on. They are available on Amazon. You could even make one yourself. I would bring one with me. I wouldnt, necessarily, wear it the whole time. I would definitely have it with me so I could add a layer of safety. If I feel like I cant keep my distance from people and other people arent wearing masks, then that would be the time I would want to put on a face shield. The real time to need them is when youre around people who arent wearing masks. I think you need to have something that will help you add a layer of protection if someone else isnt doing their part. That, for me, would be a face shield."

WHAT ABOUT STAYING AT A HOTEL?

Q: What is the general guidance?

CDC: If staying at a hotel, then check the hotels COVID-19 prevention practices before you go. When you are there, limit close contact with others in the lobby or other common areas, take the stairs instead of the elevator and choose contactless options for check-in when possible.

Q: Ive arrived at my destination. Are there any inside surfaces at my lodging I should wipe down as a precaution?

Hartmann: "If youre really set on taking matters into your own hands, focus on high-touch surfaces (keys, doorknobs, light switches, maybe remote controls)."

Q: What should I look for when booking a hotel?

Landon: "The most important thing is to look on the hotels website ahead of time and make sure the hotel has a good written policy about COVID-19. You want to see that they require masks to be worn by staff and guests in the inside common areas all the time. You want to see that they say something about their disinfection plan in rooms. Not just cleaning them in between guests, but they are disinfecting them using an EPA-registered disinfectant and theyve trained their staff in how to do so. You want to see that they have a social distancing plan in place and they have policies for use of their common-use areas like gyms or pools. That means the hotel is taking steps to protect its workers and guests. If the hotel is taking a lot of steps to protect their workers and guests, then its less likely there will be sick people wandering around your hotel, which makes it safer.

"Its important that the hotel has a clear policy, but you want to go a step further. You want to find information on travel websites or talk to someone whos been there recently. I would want to know what is really happening on the ground.

A lot of places have policies. If you call the front desk ahead of time and they have no idea what the hotels policies are, then thats a bad sign.

Q: Is it safe to use a hotels pool?

Landon: "Pools are not inherently bad. Chlorine in pools should kill COVID-19. Thats not a problem, but people dont wear masks when they are in pools. In general, the recommendation in Illinois is that pools are not open for recreation right now, but could be opened for exercise.

"Look for sun loungers to be spaced apart, signs saying the pool is not allowed to be used for recreation, only for exercise, and a limited number of swimmers can be inside at one time. If you scope it out and it appears you can safely do that, then, sure, go ahead and swim some laps."

Q: What about camping?

CDC: Going camping at a time when much of the United States is experiencing community spread of COVID-19 can pose a risk to you if you come in close contact with others or share public facilities (like restrooms or picnic areas) at campsites or along the trails.

Q: What if Im staying with family?

Landon: "Take care of yourself. Be pretty socially distant from people in the week leading up to your trip. If your family is really, really anxious about your visit, then plan to leave a few days early and take a break in a hotel for five days before you stay with family. And get tested, maybe, if everyone is really concerned."

PACKING

Q: What are some precautions to take for any type of travel?

CDC: Consider the following when leaving your home:

- If taking prescription medicine, then bring enough to last you for the entire trip.

- Pack hand sanitizer with at least 60% alcohol.

- Bring a cloth face covering to wear in public places.

- Prepare food and water for your trip. Pack nonperishable food in case restaurants and stores are closed.

- Follow state and local travel restrictions. Check state and local health department information at home, along your route and at your destination.

RETURNING HOME

Q: OK, Ive made it back home after my trip. How can I prevent the entire trips germs from ending up inside my living space?

Hartmann: "Again, wash your hands when you return. Consider disinfecting high-touch objects that you may have had with you or objects that other people outside your trusted circle may have handled, if you intend on using them again very soon."

Landon: "If you come home from a trip, then assume youve been exposed (to the new coronavirus). Get tested five to seven days after your last exposure, stay home for a little extra time. If I was going to travel like that this summer, then I would book another week off afterward so that I wasnt spreading anything that I might have picked up."

OK, THIS IS HARD

Q: My partner wants to travel this summer, but Im unsure about it. Can you suggest some ways we can have a conversation and try to understand each other?

Bohnert: "Partners should strive to appreciate what their partners would and would not feel comfortable doing. It is also important to understand where those concerns come from. Does a partner have a health condition that makes them more vulnerable? Is a partner worried about losing time away from work and reductions in salary if they are exposed? Is your partner worried about the potential of encountering racism? Are they concerned about whether there would be adequate medical care in the place where they are visiting? If one partner is particularly uneasy with one locale, perhaps another that is more familiar, closer to home or involves less time away could provide a more comfortable escape. The more you can understand what specific things make your partner uneasy about traveling, the easier it will be to come up with some options that may be more palatable if one of the partners feels strongly about the need to get away."

Q: After months of sheltering at home, Im now afraid to head out into public and be around other people. What can I do to make a trip away from home seem less stressful?

Bohnert: "To start, I would encourage people to normalize these stressful feelings. After all, we have been told to avoid people and shelter at home to prevent getting sick. So heading out in public runs counter to the advice we have been heeding over the past three months how could we not feel nervous about it?

It would be hard not to feel unsettled by the prospect of being in public after all the precautions we have been asked to take. So dont judge yourself for feeling uncertain.

Dr. Amy Bohnert, Loyola University Chicago:

"Next, try and pinpoint exactly what makes you feel uncomfortable. Is it being in closer contact with others? Fears of dining out? If you can figure out what makes you feel uneasy, you may be able to control some aspects of that situation that will make it feel more manageable. As with most things, when we feel anxious or concerned about a situation, we may seek to avoid it so we dont have to feel anxious. This, of course, reinforces that the situation is something to be feared because when we avoid it, we dont feel worried. So figuring out what you can control wearing a mask (properly), washing/sanitizing your hands and finding less crowded outdoor places where you can better manage how close you have to get to others may make the decision to get out more palatable. All these behaviors will decrease (but not eliminate) the likelihood you get infected if you encounter someone who is contagious."

Q: How can we have a fun, productive summer as a family if we decide to not take a vacation and choose, instead, to stay home?

Bohnert: "For many people, traveling introduces a lovely element of novelty to our lives. We get to see different scenery, eat different foods and have new experiences. With all the novelty we are currently facing and the uncertainty that lies ahead, the risk incurred by traveling may be more than families are ready for during challenging time. But finding little ways to enjoy the spaces and people around you, even while distancing, is important.

"There are many lovely places to explore in the Chicago area during the summertime that provide a nice respite from our homes. Some are closed but may be reopening in the coming weeks. The botanic gardens and forest preserves are lovely, nature-filled spaces. Some of our renowned Chicago university campuses also have splendid grounds in which to stroll. Springfield is a bit farther away but a great place to explore for history buffs, as is Cantigny in the western suburbs."

Consider setting some up some new family rituals bike rides, walks to look for birds, berry picking and picnics can all be nice ways to escape.

Continue reading here:
Should you travel this summer? Heres a guide to vacation amid the coronavirus pandemic. - Peoria Journal Star

Read More...

Genetics and race: An awkward conversation during volatile times – Genetic Literacy Project

June 26th, 2020 4:50 pm

In these fractious times, when we are confronting the reality of systemic racism, how can we have an informed discussion about genetics and race?

One way is to calmly state the increasing evidence of meaningful genetic differences between human populations and then engage in honest and robust debate about the social and political implications, if any, of such inter-group divergence.

Back in the real world, meanwhile where open discussion of race and biology is largely taboo (a state of affairs recently exacerbated by DNA pioneer James Watson) a better idea might be to quickly change the subject. So what about the weather, eh?

But battening down the hatches and sitting out the storm isnt really an option. For a start, it would mean blithely ignoring the deluge of data from the recent revolution in molecular biology about our species evolution and of the genetic divergence of separate human populations over time. More importantly, it would also miss the opportunity to genuinely level the playing field for those very peoples most marginalised by an undeniable history of prejudice and neglect.

Note, though, the numerous alternatives for race already employed above: populations, groups, peoples (to which ancestry, descent and the like could also be added). Far from simply being politically correct euphemisms for a tainted term, it is important to distinguish between the word race as it is socially used say, the Black/African American, Native American, White, etc. racial categories used in the US census from the biological sense, used to describe distinct populations within a species.

Because of the historical misuse of the term race, this is an important distinction to make. In 19th century Britain, for example, two groups who would now be simply lumped together as White were regarded as separate biological races namely, and complete with the picturesque descriptors of the time, the careless, squalid, unaspiring Irish and the frugal, foreseeing, self-respecting Scots. (Full disclosure: my own genetic ancestry is of the careless, squalid and uninspiring variety.) A more modern perspective, however, does not deny the existence of genetically distinct indigenous British populations such groupings do indeed exist rather, it avoids describing them in meaningless racial terms. Similarly, the idea of an overarching Black race utterly fails to capture the genetic diversity of African (or African-descended) peoples, irrespective of how we are now able to distinguish genetically related groups within the wider human population of Africa.

Nor is this simply overly-sensitive quibbling over the meaning of a word. Historically, race was often used synonymously with varieties, breeds or sub-species (in the Descent of Man, for instance, Darwin considers at great length what was then still an open question: Arguments in favour of, and opposed to, ranking the so-called races of man as distinct species). But whether we like it or not, words have power, and once-acceptable descriptors of human inter-group variation now carry obvious egregious connotations (such as the slur half-breed).

Indeed, the limitations of language have long been a bane of everyday discussion of human evolution, with phrases and concepts survival of the fittest, say, or struggle for existence inevitably being interpreted in terms of intrinsic worth. Descriptions of sub-species of flora and fauna, for instance, would ruffle few feathers; similar talk of sub-populations of human beings, however, inevitably evokes hierarchical notions of superiority and inferiority. (As a light-heartened analogy, think of the hierarchical distinction between language and dialect then tell the Germans that their language is a dialect of Dutch.)

In sum, then, anyone discussing genetics and race must be conscious of the connotations and impact of words. And this is especially true when engaging in dialogue with those with a standard social science conception of race, one in which human evolved biology is seen as irrelevant to social issues a paradigm, moreover, in which the very idea of human biological difference is treated with the utmost suspicion. Given this latter mindset and the human tendency towards righteous indignation it is hardly surprising that many liberal-minded people react badly when confronted with arguments about human difference that they perceive (rightly or wrongly) as morally offensive. If worthwhile or meaningful discussion of genetics and race is to proceed, therefore, it is beholden on geneticists and their ilk to take this into account not through political timidity but through simple courtesy and common-sense.

Of course, as pointed out above, such is the toxic nature of this topic that open discussion is often avoided, especially by those cowed by the likely reaction of their peers. In this respect, political scientist James Flynn discoverer of the eponymous Flynn effect of rising IQ over time points to the counterproductive nature of intellectual censorship: [T]hose who boycott debate forfeit a chance to persuade. They have put their money on indoctrination and intimidation. A good bet in the short run but over the long course that horse never wins.

The sort of censorious indignation highlighted by Flynn also has another detrimental effect: it opens a space for nationalistic populists and race supremacists to claim they are simply telling it as it is or bravely saying what others are too scared to admit. The losers here, of course, are the very people that the taboos were designed to protect those marginalized minorities likely to face greater prejudice from emboldened bigots.

Moreover, Flynns own work provides a further explicit example of how such taboos can have counterproductive consequences; if Flynn had been unable to research the causes of reported racial differences in IQ he would never have discovered the Flynn effect, the best evidence we have of environmental influences on intelligence (and of how improvements in impoverished environments can lead to dramatic changes in IQ scores over time).

This points not only to the benefits of openly addressing sensitive subjects, but also to a possible way to assuage some of the suspicion that surrounds genetic research into inter-group difference that even if such differences are shown to exist, this does not dictate any particular social or political response. Facts do not determine values.

At the same time, however, facts can certainly inform social policy. Take, for example, the overwhelming evidence of strong genetic influences on academic achievement. Contrary to what many might pessimistically assume, this genetic evidence does not mean that nothing can be done for those currently failing in the education system. As the Flynn effect shows, environmental change does make a difference, despite the high heritability of IQ.

Indeed, the strong genetic determinants of educational attainment are much less straightforward than they appear. For example, some studies that indicate a causal link between genes and learning hinge on the observation that older mothers have offspring who are more likely to succeed in school. As older mothers also have fewer children (with whom they can devote more time and resources), the relevant genetic influence here pertains to fertility rather than academic smarts. Given this, and given a political desire to raise academic attainment amongst specific groups, ameliorative social policy could focus on womens reproductive health and opportunities in marginalised communities.

Be this as it may. The point is that genetic facts including evidence of genetic differences between racial populations carry no necessarily social or political implications. Nevertheless, these same genetic facts may help highlight obstacles to achieving desired social outcomes, and could provide information that assists in overcoming them. In this respect, just as greater awareness of social and environmental barriers can assist in designing policies to reduce inequalities, so too could greater recognition of possible genetic hurdles to improved life outcomes.

In the past in the era of Social Darwinism and eugenics hereditarian political beliefs equated biology with destiny. Unfortunately, much of the present-day antipathy to human genetic research appears premised on a similar erroneous belief: that if human behavior is under the influence of biology/genes then certain social outcomes, such as disparities in wealth or status, are inevitable. Hence the desire to denigrate genetic research that touches on the raw nerve of race for, as many well-intentioned egalitarians may mistakenly believe, if meaningful differences between different peoples really do exist, then the goal of greater equality could prove unattainable.

The biological study of human behavior is notoriously fraught hardly surprising, given that fallible humans are both the subject and the object of scrutiny. Furthermore, given the egregious history of political ideas based on supposed facts of human biology, the results of human behavioral research are often held to a higher standard of proof and most especially with research relating to politically sensitive topics, such as race, gender or sexuality.

Whether always warranted or not, such critical inspection comes with the territory; indeed, one higher standard that human geneticists can impose upon themselves is to understand the motivation of the opposition, however wrong-headed this might appear. Such awareness would not mean avoiding discussion of troublesome topics but it might avoid discussing them in ways more likely to inflame than inform.

A version of this article was originally published by the Genetic Literacy Project on Feb 13, 2019.

Patrick Whittle has a PhD in philosophy and is a freelance writer with a particular interest in the social and political implications of modern biological science. Follow him on his website patrickmichaelwhittle.com or on Twitter @WhittlePM

Here is the original post:
Genetics and race: An awkward conversation during volatile times - Genetic Literacy Project

Read More...

One Run Can Alter 9,815 Molecules in Your BodyHeres Why Thats Important – runnersworld.com

June 26th, 2020 4:50 pm

While its undeniable that logging miles has major health benefits, scientists dont exactly understand how it affects your body at the molecular levelbut researchers are attempting to figure that out.

A Stanford University study published in Cell set out to determine what happens in the body just after exercise, and try to get one step closer to explaining exactly what makes exercise so good for your health.

In the study, 36 people aged 40 to 75 completed a peak VO2 testwhich measures maximum oxygen consumption during intense exercise as a marker of aerobic fitnesson a treadmill. Before running, researchers sampled their blood. Then, after about 9 to 10 minutes of running, the participants blood was sampled multiple times: immediately after exercise, and then 15, 30, and 60 minutes after they reached their peaks.

Researchers then completed multi-omic profiling, where they looked at the participants blood to see how exercise affected molecular changes in the cellsincluding how exercise affects immune cells and plasma. Over 17,000 molecules were measured, and 9,815 moleculesmore than halfshowed significant change, Michael Snyder, Ph.D., professor and chair of genetics at the Stanford University School of Medicine, in Stanford, California, told Runners World.

Exercise has a lot of health benefits, but nobody knows how exercise really works, Snyder said. Im not saying our study figured it out, but it gives us a window into whats going on in the body.

Researchers were able to see changes in oxidative stress, which is a harmful chemical process when theres too much of it. They also saw immune system markers and molecular markers of healing and inflammation go up right away as the body began to recover.

These results give a window into different systemic events, such as the potential to look into how oxidative stress affects aging, how exercise affects your immune system, how your body reacts to metabolic stresswhich occurs in exercise as energy depletes, leading to accumulation of lactic acid in musclesand how muscles are engaged during exercise as researchers work to further study the effects exercise has on the body.

I do view it as just trying to work out the choreography of whats going on, Snyder said. Its like a symphony, maybe the violins start off first, then the next instrument and the next come in.

[Smash your goals with a Runners World Training Plan, designed for any speed and any distance.]

This kind of testing can give researchers the ability to see whats happening in peoples bodies, such as seeing how muscle markers and markers for cardiovascular disease are all stimulated and engaged.

While we know that exercise is important for heart health, its not exactly known how it benefits your ticker. This is something researchers hope to use these findings to study more in the future, Snyder said. And, while this test was only done using a treadmill stress test, researchers will look at how molecules in the body are affected by other types of exercise.

Results showed that peoples fitness and health levels were consistent with how much exercise affected the molecules in their bodies. For example, people that were healthy had similar molecular changes before and after exercise; those who were insulin resistant (prediabetic and diabetic) didnt have as large of an immune response, which may be able to show how exercise affects this condition or helps predict the onset of diabetes.

And, through these blood samples, the molecular patterns found anemia that other testing hadnt picked up in one healthy individual, Snyder said.

So what can this tell you about your health? Right now, researchers are still figuring that out. But as the molecules change, they are able to see things like how different systems in your body engage during exercise, how your cardiovascular pathways are affected, and when different types of fat burning may occur. All of these elements give researchers a better look at how exercise engages the entire body.

Were looking at the details of how the symphony is able to play, Snyder said.

In the future, the researchers hope that a version of molecular profiling can be used as a way to measure aerobic fitness and along with typical treadmill testing.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Read the original:
One Run Can Alter 9,815 Molecules in Your BodyHeres Why Thats Important - runnersworld.com

Read More...

Human Genetics Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 – Cole…

June 26th, 2020 4:50 pm

Genetics is that the study of genes, their functions and their effects. Among the varied sorts of biology like genetic science, developmental genetic science, population genetics and quantitative genetic science, human genetics is that the study that deals with the inheritance happens in folks. It encompasses a range of overlapping fields like classical biology, genetics, genetic science, genetics and plenty of additional.

The Human Genetics Market is expected to exceed at a CAGR of 9.5% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/human-genetics-market

The Human Genetics Market is segmented on the lines of its methods, product, applications, end-users and regional. Based on methods segmentation it covers cytogenetic, molecular, presymptomatic and prenatal. Based on product it covers Consumables, devices and accessories. Based on end-user analysis it covers hospitals, clinics, research centers and forensic departments. Based on application it covers research, diagnostic and forensic science and others. Based on Others it covers Hysteroscopy Instruments Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

This report provides:

1) An overview of the global market for Human Genetics Market and related technologies.2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.3) Identifications of new market opportunities and targeted promotional plans for Human Genetics Market.4) Discussion of research and development, and the demand for new products and new applications.5) Comprehensive company profiles of major players in the industry.

Report Scope:

The scope of the report includes a detailed study of Human Genetics Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Agilent Technologies, Bode Technology, GE Healthcare, Illumina, LGC Forensics, Orchid Cell mark, Inc., Promega Corporation, QIAGEN N.V., Thermo Fisher Scientific, Inc. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Human Genetics Market has been segmented as below:

The Human Genetics Market is Segmented on the lines of Application Type, Methods, Product Type, End-user and Regional Analysis. By Application Type this market is segmented on the basis of Research, Diagnostic, Forensic science and Others. By Methods this market is segmented on the basis of Cytogenetic, Molecular, Presymptomatic and Prenatal.

By Product Type this market is segmented on the basis of Consumables, Devices and Accessories. By End-user this market is segmented on the basis of Hospitals sector, Clinics sector, Research centers sector and Forensic departments sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

Request Sample Report: https://www.marketresearchengine.com/human-genetics-market

The major driving factors of Human Genetics Market are as follows:

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Human Genetics Market.

2) Identify growth segments and opportunities in the industry.3) Facilitate decision making on the basis of strong historic and forecast of Human Genetics Market.4) Assess your competitors refining portfolio and its evolution.

Other Related Market Research Reports:

Depth Filtration Market 2019| Size, Industry Share, Approaches and Forecast By 2024 Market Research Engine

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

See the original post:
Human Genetics Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 - Cole...

Read More...

Crunching the numbers: what are the real risks of dying from Covid-19? – Telegraph.co.uk

June 26th, 2020 4:50 pm

While the risks for young healthy people are comparatively low, other experts warn about reading too much into the data recorded during lockdown.

Dr Peter Ellis, a lecturer in molecular genetics and reproduction at the School of Biosciences at the University of Kent, notes that Sir Davids data represent only the residual risk not the natural one.

The reason relatively few people have died of Covid is because only a small percentage of the population have had the disease, he says

A more appropriate conclusion in my view would be to rejoice that the lockdown has done its job and thus kept the overall risk of death low.

Also, the fact that younger demographics are comparatively protected does not mean it is necessarily safe for younger people to mix more freely.

This may be true, but it does rely on our ability as a society to cocoon and protect more vulnerable demographics: a feat not achieved by any country so far, warns Dr Ellis.

In any calculation of mortality risks, it can be also misleading to compare infectious and non-infectious causes of death. Car accidents and bombing raids have very different characteristics to viruses and bacteria.

Infectious disease risk is socialised rather than individual, says Dr Ellis. My actions affect others' chances of death as well as my own.

Protect yourself and your family by learning more aboutGlobal Health Security

Read more:
Crunching the numbers: what are the real risks of dying from Covid-19? - Telegraph.co.uk

Read More...

Coronavirus: How COVID-19 is mutating across the world – Sydney Morning Herald

June 26th, 2020 4:50 pm

Normal text sizeLarger text sizeVery large text size

Nadia had a cough and it wouldnt go away. She didnt feel like eating. X-rays and ultrasounds, blood work, all turned up nothing. So a decision was made to test Nadia a four-year-old Malayan tiger at the Bronx Zoo in New York for the latest bug going around, the one that had already put much of the world, including her zoo, into lockdown: COVID-19.

On the other side of the globe, a 42-year-old woman in Melbourne had come down with similar symptoms to Nadia the same dry cough, the fatigue. And, when the tests came back from the labs, the sample of the virus found in both human and tiger was near identical too. Within days, another swab with that tell-tale genetic signature would be extracted from a 21-year-old in Taiwan.

How does the same strand of virus end up in a woman in Melbourne, someone in Taiwan, and a tiger in the Bronx?

Unlike historic plagues, COVID-19 is not spreading in a straight line, from house to house or country to country. Instead, versions of the virus each with their own tiny genetic tweaks are jumping from continent to continent via plane (and cruise ship), and crossing back on each other. The story scientists who specialise in reading COVIDs genes see is that of the worlds first truly globalised pandemic.

Since researchers in Wuhan, China, where the outbreak began, first published the genetic code of the virus, hundreds of labs around the world have followed suit. Their efforts to join the dots among patients, under the microscope as well as on the ground, mean this pandemic is being tracked like never before in real time. Already the family tree of COVID-19 is helping us understand where the outbreak came from, how it took hold in different continents and where its going next.

DNA detectives have tracked one distinct strand of coronavirus from Wuhan through Europe, Australia and Taiwan all the way to Nadia the tiger, pictured, at the Bronx Zoo in New York.Credit:Stephen Kiprillis, Kirsten Burghard

There are more viruses in the world than stars in the sky. They are found in almost every corner of the Earth, they fill its oceans. If lined up, side by side, scientists say they would fill our galaxy too. Most of them cant infect us and the few that can we catch mostly from animals in that knife-edge moment of chance when a pathogen long circulating in one species leaps to another.

Ten thousand times smaller than a grain of sand, viruses can drive forward evolution and unleash hell think of them as zombie shells of protein waiting to spring into action.

Theyre half living, half dead, says Professor Seshadri Vasan, from behind several Get Smart-style levels of security at the CSIROs dangerous pathogens lab.

Unlike bacteria, which can thrive wherever it's warm and wet, viruses need a host to survive. They are the pirates of the microscopic world, commandeering the cellular machinery of other organisms to make copies of themselves and spread.

All they need is a way in.

Thats why its Mission Impossible here at the lab, Vasan says.

Some time in late 2019, a coronavirus now known as SARS-CoV-2 found a door into the human genome this tiny ball of protein evolved a spike able to unlock our cells by binding to ACE2 receptors, a type of enzyme found throughout our bodies. In the bustling city of Wuhan, the virus jumped from an animal into a person, most likely through the handling and slaughter of wildlife for the meat, fur and traditional medicine trade. From there, the germ spread like wildfire between humans infecting more than six million people and killing 400,000 within its first six months.

"Trouble wrapped in protein": Inside its spiky outer shell the coronavirus contains a folded-up strand of RNA.Credit:Kirsten Burghard

Beneath the coronaviruss signature spikes, youre looking at an envelope of fat encasing a long strand of RNA. Like our own double-stranded DNA, this holds the viruss instruction manual for making more copies of itself.

Its like a manuscript written in a language made up of only four letters: A, C, G and U, which is more commonly called T, Vasan says. How they are arranged on the page can change how the virus behaves.

SARS-COV-2s manual is long made up of 30,000 letters or nucleotides. By contrast, the influenza strain that caused the worlds last pandemic in 2009, swine flu, was just 13,500 letters long, Vasan says. This is more than twice the size, its a very big virus.

It is also more deadly.

Once a virus is inside a cell, it sets up shop, replicating at speed. Imagine photocopying this viral manuscript, Vasan says but each copy is then used to make the next. Before too long, mistakes smudges or missing letters will start to creep in. These typos are known as mutations. Some of them slow the virus and are dropped from the text over time. Most are silent they dont affect the viruss structure or function and so you can still understand the sentences. But then there are the rarer mistakes, the ones that improve the virus.

Perhaps it's a really bad manuscript, laughs Professor Francois Balloux, who heads up the genetics institute at University College London.

Before it emerged in humans, scientists say two key mutations had already primed SARS-CoV-2 to jump species lines and spread further than the other two dangerous coronaviruses to come before it, SARS-CoV-1 and MERS-CoV. One change allowing the virus to fuse cells together and tunnel its way through the body faster came down to just three letter changes in its RNA code, says Dr Denis Bauer at the CSIRO.

But now that it is circulating in humans, scientists say the coronavirus is mutating at a fairly stable rate about 20 mutations a year, Balloux calculates. Thats a little faster than he expected, although not as fast as less predictable viruses such as influenza, which requires an updated vaccine every season to keep up with all its mutant stains.

Runaway COVID-19 outbreaks in parts of Europe and the Americas have fuelled speculation that more deadly or infectious strains of the virus may be circulating already some early studies have suggested as many as 30 kinds of SARS-CoV-2. But most scientists stress the mutations so far havent changed how the virus behaves.

Loading

Nadias particular virus, for example, when examined under the microscope by Dr Leyi Wang at the University of Illinois, had racked up just six recurrent mutations or protein changes since it travelled out of Wuhan to her zoo in New York.

Critically, Vasan notes, mutations in the RNA code or even observed in how the virus behaves in the petri dish must be matched against clinical outcomes in patients to truly warrant the distinction. Otherwise they might look like theyre having an effect when theyre not, he says. Im not seeing anything sinister in the mutations so far.

At the Bedford lab, which pulls together global genomic data on COVID-19 through the platform Nextstrain, Dr James Hadfield agrees. Most of the time when a virus starts to behave differently its down to its environment not its biology as it encounters different healthcare systems, population vulnerabilities and public health interventions.

Nadia's virus was traced back through Europe to the original outbreak in China.Credit:Stephen Kiprillis, Kirsten Burghard

But mutations do come in handy for tracking the virus. Over time, differences between samples (good, bad and not worth mentioning) build up, leaving tiny molecular clues for scientists to follow each genome is timestamped to when (and where) it was collected.

The small team behind Nexstrain works around the clock to crunch this data when Hadfield signs off in New Zealand, Dr Emma Hodcroft and her colleagues in Switzerland are ready to take over, followed by Dr Trevor Bedfords team in Seattle.

Hodcroft says the very first genomes out of China were just one mutation apart. Six months on, the branches of the tree still arent very long samples of the virus vary by only about 10 recurrent mutations on average and their roots all go back to a common relative: that first genome sequenced in Wuhan. Thats how scientists know the spillover from animals into humans happened recently in China, likely in November 2019.

Now weve moved from the sparks being thrown off by the Chinese epidemic, to individual epidemics starting in certain countries, Hodcroft says.

Local mutations may develop as the virus spreads in a specific community, particularly with much of global travel grounded, but no country has a distinct national strain yet. There is no US strain or Australian strain, Balloux says.

On April 1, a woman was swabbed in Melbourne. Within days, virtually the same genetic signature would be extracted from Nadia in New York.Credit:Stephen Kiprillis, Kirsten Burghard

In Australia, COVID-19 cases are comparatively few but our virus is among the most sequenced in the world. More than 60 per cent of all confirmed Victorian cases have now had their sample sequenced, Dr Sebastian Duchene of the Peter Doherty institute for Infection and Immunity says. And in NSW, genomic detectives have tracked early cases in Australia back to Iran as well as China, based on distinct mutations.

When you compare Australias viral tree with somewhere like the US, you see more genetic diversity, Hadfield says most cases tend to be imported from overseas, giving us not just one initial case or patient zero but hundreds. But where clusters emerge without a clear source, genomic data can help contact tracers crack the case.

Sequencing or tracking the viruss genetic passport has now revolutionised how health authorities fight pandemics, says Professor Benjamin Howden at the Doherty Institute, and will become critically important as countries ease restrictions. In some cases in Victoria, he says, clusters in which people had no known links to each other were uncovered after the lab team traced a connection in the viruss genes.

Usually, when you do contact tracing, everyone in a cluster has the same virus, Duchene says.

This observation is what makes Nadia and her Melbourne strain so strange, on the face of things.

Every dot below is a Victorian case, and every line is a link between that patient and another made by contact tracers. Dots of the same colour share the same genetic virus signature as others. Some clusters, such as the large 75-person outbreak that erupted in March (shown in red down the bottom) were also linked genetically to other clusters although no connections were found on the ground.

Victorian clusters between January 25 and April 29 were linked by genetics as well as contact tracing. Credit:Source: The Doherty Institute

Still, the worlds genomic dataset on COVID-19 is both museum and live recording its not over yet.

Scientists stress they have only part of the picture most virus lineages infecting people will not be sequenced. Even that first sample published in Wuhan did not come from a definitive patient zero but one of the earliest known cases: a 41-year-old worker in the wet market where the virus is suspected to have first broken out or circulated.

We might not ever find the very first because so many people get no symptoms or mild symptoms, Balloux says.

Loading

Vasan warns theres a danger in any outbreak: in the race to find a cure, scientists could pick up the first sample that comes their way and run with it - in the wrong direction. When the Doherty Institute became the first lab outside China to sequence and grow the virus, it was passed like a baton in a relay, straight to Vasan at the CSIRO for mass production as his team test some of the worlds top vaccine candidates.

But in the back of my mind, I wanted to be sure what we were working with was a typical strain, Vasan says.

So, he called in experts in artificial intelligence, including Bauer, to help screen samples for unusual mutations, particularly in areas where changes could cause a real difference to how the virus behaves, such as in its unstable and much-discussed spike. The results were reassuring they found that the first Wuhan strain, now used all around the world as a reference, was a good sample, as were the baseline strains used in Washington, Sydney, Melbourne and elsewhere. Even labs in the UK use our first Victorian strain now, Vasan says.

But they did find some outliers, including a NSW sample which contained a curious deletion. Another, collected in Italy, had mutations in common with both a Sydney virus cluster and one on the other side of the world in Chongqing, China.

Were not sure why, Bauer says. It could have been a recombination, where someone is infected with two lineages of virus at the same time that gave rise to this particular version.

The probability of two different viral lineages evolving the exact same mutations on their own is very low, Bauer says, though Vasan notes not impossible.

Influenza, meanwhile, spits out hybrid strains all the time on a much bigger scale known as reassortment. While coronaviruses can also recombine, they are less likely to produce anything too radically new in one go, Balloux says, because these spiky pathogens come with their own in-built proofreader a kind of molecular quality control.

Bauer likens it to the difference between using a cookie cutter to make Christmas biscuits and letting your toddler loose kneading the dough into the right star shape. Thats probably what allowed it to become larger and more sophisticated than other RNA viruses, she says.

Nadias nasal swabs were tested in two different labs, the University of Illinois and Cornell University, then driven through the night to a government lab for further checks all came back positive.Credit:Stephen Kiprillis, Kirsten Burghard

In Nadia the tiger, one strand of COVID-19 that had stretched all around the world reached the end of the line the big cat is thought to have caught it from a zookeeper without symptoms in March but did not pass it back to another human.

But she was part of a big cat cluster inside the Bronx Zoo. Nadia was tested first in early April because she seemed the sickest but five tigers and three lions would test positive in total. All are now recovering well, says Professor Karen Terio who helped co-ordinate the tests at her zoological pathology lab at the University of Illinois.

Nadia was coughing, which is an odd clinical sign for a tiger, so we had a suspicion, Terio says.

Loading

The labs virologist, Leyi Wang, who had to devise a whole lab test for the felines, admits Nadias positive still came as a shock. The zoo had already been shut for weeks when the tiger got sick [at the end] of March Now were looking at the other cats. The tigers strain was very similar to the human New York virus but the lion samples look a bit different to the tigers. Its not clear yet how they were all infected.

Balloux notes that the fact the virus can infect other species makes it possible two different lineages human and animal could recombine into a hybrid strain down the line. Some think thats how we got COVID-19 to begin with. An old bat coronavirus might have mixed with one in a pangolin [a mammal trafficked in China] or maybe it just jumped to the pangolin or [another mammal] that has ACE2 [receptors] like humans and evolved there.

But he is not worried.

Next to the millions of human COVID-19 cases already confirmed, only a tiny handful of animals, including cats, dogs and ferrets, have tested positive and then only in mild or asymptomatic cases (or at high deliberate doses in the lab). Aside from a cluster of mink in cramped fur farms in the Netherlands, there has been no sign animals can pass the virus back to people. Experts say this suggests transmission between species (notably humans and their pets) is very weak and no cause for alarm.

So how did eight big cats fall sick all at once?

The Bronx Zoo did not answer questions on the circumstances or whether staff members had also tested positive, and Terio says that contact tracing work is ongoing and has not been disclosed to her for privacy reasons. While the cluster does offer new clues about what species are particularly susceptible to SARS-CoV-2, she thinks its probably too much of a leap to say it narrows down the search into the viruss origins.

Evolutionary biologist Professor Edward Holmes points to another cluster, this time of mink falling severely ill in Dutch farms, as the best place to start looking - mink are also widely farmed in China for their fur. Another lead could lie with the highly endangered and heavily trafficked pangolin which has been found via genomics to carry a similar (though not identical) virus. Holmes says the wildlife trade, including fur farming, remains the most likely origin of the pandemic, as happened with SARS and many other outbreaks.

CSIRO scientists are growing both the coronavirus and vaccine candidates in their lab in Geelong, Victoria as part of a global race for a cure.Credit:Stephen Kiprillis, Kirsten Burghard

Fortunately, most scientists say it is unlikely the virus will mutate into something nastier by its very nature a germ wants to spread, not kill.

Over time Vasan expects it will become milder the way past pandemic flu strains have as they adapted to their new host. But, also like pandemic flu, COVID could linger on as a seasonal problem that flares up in the cold winter months at least until it is properly stamped out by vaccination programs.

Back at the CSIROs sprawling lab in Geelong, vast stores of the coronavirus enough for at least two years of vaccine and treatment experimentation sit in high-security freezers at minus 80 degrees. A virus that mutates slowly is unlikely to lose its bite any time soon. But it's also less likely to change to evade a vaccine.

Loading

Im not worried its going to get worse or mutate out of control of a vaccine, Balloux says. Its already [spreading] out of control now. It's already bad."

Finding an effective vaccine or treatment is critical to getting the world back to some degree of normality while so many of us are still susceptible, Vasan says. Scientists developing vaccines arent closing their eyes to the virus genome much of the work is focused on areas of its molecular structure less likely to mutate.

Its like a child in a playground, were keeping an eye on it, Vasan says. That doesnt mean were worried but well keep looking back while [we work], so we know the child is still there.

Of course, for all the attention on COVID-19s genome, he stresses there is still crucial data missing matching, de-identified clinical records that could show the severity, outcome and personal risk factors of each case.

Mother Nature is running a giant experiment all around the world right now. Thats where we need to look to see what the mutations mean.

The problem, Vasan says, is that even very basic patient metadata is maddeningly inconsistent across jurisdictions, both interstate and international and no one is showing much enthusiasm for cleaning it up. Mild and moderate mean different things everywhere.

Of the many thousands of virus samples sequenced and shared worldwide, the CSIRO team managed to find just 300 with meaningful, matching patient information.

Loading

Their resulting analysis was underpowered, Bauer says, but they could already make a preliminary link between changes in clinical outcomes and mutations in the viruss spike protein. Imagine what we could do if we had more.

Only the World Health Organisation could co-ordinate an international approach to streamlining such data into uniform categories, Vasan says, but Australia could still lead the charge with some show and tell.

If we can pull this data together [nationally], we can show the world what it can teach us, he says. What we find out could change the game.

Read more here:
Coronavirus: How COVID-19 is mutating across the world - Sydney Morning Herald

Read More...

The Incredible Gene-Therapy Breakthroughs to Cure Blindness – Daily Beast

June 26th, 2020 4:48 pm

By Hemant Khanna, The Conversation

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.

Researchers at U.S.-based Editas Medicine and Ireland-based Allergan have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.

According to the World Health Organization, at least 2.2 billion people in the world have some form of visual impairment. In the United States, approximately 200,000 people suffer from inherited forms of retinal disease for which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.

I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances because my laboratory is focusing on designing new and improved gene therapy approaches to treat inherited forms of blindness.

Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.

The second reason is that retinal tissue in the eye is shielded from the bodys defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.

In recent years, breakthrough gene therapy studies paved the way to the first ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease, Leber congenital amaurosis Type 2.

This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect lightblindness.

The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involved inserting a healthy copy of the mutated gene directly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.

Although the treated eyes showed vision improvement, as measured by the patients ability to navigate an obstacle course at differing light levels, it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.

Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthrough gene editing technology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.

Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the genecalled CEP290to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.

One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.

The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.

These studies led to the formulation of the first ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.

To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.

An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.

This approach involves using shorter yet functional forms of the CEP290 protein that can be delivered to the photoreceptors using the viruses approved for clinical use.

Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cells DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.

Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.

In another study just reported in the journal Science, German and Swiss scientists have developed a revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.

The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.

The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.

In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.

This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.

Hemant Khanna is an associate professor of ophthalmology at the University of Massachusetts Medical School

Read more:
The Incredible Gene-Therapy Breakthroughs to Cure Blindness - Daily Beast

Read More...

FDA Official: New "Playbook" Needed for CMC Reviews of Gene Therapy Products – Xconomy

June 26th, 2020 4:48 pm

XconomyNational

A new playbook is needed to ensure consistent chemistry, manufacturing, and controls (CMC) reviews for gene therapy products, the lack of which is hindering the development of these products, asserted a top official at the US Food and Drug Administration .

Now is the time to get things right asserted Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, who spoke at a 15 June virtual Drug Information Association annual meeting session on how innovation can help overcome hurdles for these products.

The sessions moderator, Nancy Myers, president of Catalyst Healthcare Consultants, asked the panelists to describe some of their main CMC constriction points in developing gene therapy products, and to identify potential solutions. The other panelists were Karen Walker, the senior advisor for cell and gene therapy at Genentech, who formerly was at Novartis (NYSE: NVS) and worked on the development of Kymriah, and Michael Paglia, director of CMC for ElevateBio.

Myers said that there are two common types of roadblocks to getting gene therapy products through the development pipeline, and these are logistical and technical challenges. The logistical challenges are having a well-trained workforce, managing global distribution networks and ensuring products are transported in cold temperatures, while the technical challenges are ensuring the quality of the starting materials and scaling up production from the research site to commercial manufacturing.

Another roadblock is the lack of standards and lack of a regulatory framework for these products. Myers said that this is a new and growing field and companies are trying to lay the track as they are trying to drive the train down the track at the same time.

CONSISTENT CMC PLAYBOOK NEEDED

Myers first asked the panelists to discuss what they see as constriction points in manufacturing gene therapy products. In response, Marks said that a lack of consistent reviews is hindering their development.

It has become apparent over the last couple of months that, while we have excellent reviewers, it does happen that people can have differences of opinion. I think we will have to come around and have a clear playbook so that everyone gets the same advice especially as we have grown. I know that someone out there will say, we had two different CMC reviewers and two differences pieces of advice. I am not going to argue with that. That is an issue here. As we come to the post-COVID period we should to try to have more unity in what comes from our CMC reviews. I cannot say the problem is solved but the problem has been identified and is amenable to solutions.

He further noted that the lack of clear regulatory pathway for these products is a major roadblock in accelerating their development. We do not have the preclinical pathways set up and the clinical set up and the regulatory paradigm is yet to be fleshed out. Now is the ripe time to get things right.

Marks also noted some of the manufacturing challenges in the cell and gene therapy space: We are in a place where our current vectors are limiting what we can address in terms of our ability to product them on a very large scale, and what will probably take some years to get there. On the other hand, the piece that really interests me is how do we deal with hundreds and thousands of rare diseases that we cant address right now through the production of gene therapy products where we simply do not have the manufacturing capacity to be able to produce these products in a rapid manner because we just dont have the systems.

MORE ON WHY DEVICE-LIKE REVIEW COULD HELP

Marks expanded on an idea he had suggested in February, that reviews for gene therapies should be more aligned with the device model. (Also see Individualized Gene Therapy: US FDA Considering Device-Like Manufacturing Approval Process Pink Sheet, 28 Feb, 2020.)

It is becoming increasingly clear that for cell and gene therapies, the manufacturing is more like a device paradigm with continued innovations, he said. With a traditional drug you come up with a chemical process to make a small molecule and you are probably using the process similarly across the lifecycle, but you are not constantly finding ways to do things that fundamentally change the yield or quality of a product. Here we have issues that manufacturing changes can potentially change the product for the better.

He added that we have to find some balance here between the traditional drug manufacturing model of once and done to something that is asking you go through multiple cycles of a device every two to three years where you are changing the technology. With device cycles, you may have multiple generations of the device over years. With a device you can measure things nicely, with biologicals you cannot measure easily.

Walker concurred that these are not well-characterized products and so we need to invest heavily in analytics so that we can gain product and process understanding so that we can facilitate rapid changes that we know will not negatively impact the health of the patients.

KYMRIAH TECHNOLOGY ALREADY OUTDATED

Walker said a constriction point for her is not keeping up to date with current technologies. She said that a technology platform developed today may be outdated tomorrow. The rate of change of innovation is now every two or three years, she said.

That mirrors the rate of the device cycles that Marks mentioned, lending further credence to the idea that cell and gene therapies should be reviewed similarly.

Walker said that the technology that Kymriah has been based on has been eclipsed. It took three years for start up to approval and now no one is using the same technology as the basis for their platform. The technology and the state of the art is advancing very rapidly. This is a challenge for regulators. They need to understand we can be early adopters of these technologies without changing the product.

Kymriah was the first gene therapy product approved to treat B-cell acute lymphoblastic leukemia (ALL) and diffuse B-cell lymphoma (DLBCL). The product used spherical beads to isolate, activate and expand T-cells. After the cells are modified, they are infused back into the patient. The FDA approved the drug in August 2017 (Also see FDAs NDA And BLA Approvals: Kymriah, Vabomere, Cyltezo Pink Sheet, 1 Sep, 2017.) and the EU approved it in June 2018. (Also see First CAR T-Cell Therapies OKd In EU: Novartiss Kymriah And Kites Yescarta Pink Sheet, 29 Jun, 2018.)

Walker said there also needs to be flexibility from regulators to allow new technologies. The technology is advancing very rapidly, and that is another challenge for regulators. To understand where they can have flexibility.

AVAILABLE TALENT POOL A MAJOR CHALLENGE

Michael Paglia, senior VP of CMC operations for ElevateBio, said that his main constriction point has to do with staff and talent and supply chain and the cost of goods and quality and access to capacity.

To address the capacity challenges, the company came up with a model of funding multiple start-ups and to utilize the same R&D and manufacturing facility, rather than individual companies whose cell and gene therapy R&D is slowed by the need to build their own lab and production spaces. (Also see ElevateBio Brings Centralized Model To Cell And Gene Therapy Scrip, 13 May, 2019.)

We took the approach to build our own and to build an integrated research to support out cell and gene therapies.

The company in July 2019 announced a partnership with Massachusetts General Hospital. Under the agreement, which runs for 10 years, MGH has access to ElevateBios research, process development and manufacturing facility in Waltham, MA, for development and production of cell and gene therapies.

Paglia said that there are now more skilled employees compared to seven or 10 year ago, but that it is still challenging to find talent. We are fortunate to have experienced staff. It is necessary to put procedures in place to have rigorous training. Training is very important, and we are involved with local universities as well to give them an idea of if you come out of this how do you get into cell and gene therapy.

This article was first published in the Pink Sheet on June 18, 2020.

Image: iStock/IvelinRadkov

Joanne Serpick Eglovitch is a senior editor for Pink Sheet where she writes about manufacturing and quality issues.

See the original post:
FDA Official: New "Playbook" Needed for CMC Reviews of Gene Therapy Products - Xconomy

Read More...

Gene Therapy Market: Predictable To Witness Sustainable Evolution over 2020-2030 – 3rd Watch News

June 26th, 2020 4:48 pm

The Gene Therapy Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Gene Therapy market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Gene Therapy market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Gene Therapy report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/39

The research report also focuses on global major leading industry players of Gene Therapy market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Gene TherapyMarket Key Companies:

GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc.

The predictions mentioned in the Gene Therapy market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

The report provides an in-depth analysis of the Gene Therapy market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/39

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Gene-Therapy-Market-By-39

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622

Continue reading here:
Gene Therapy Market: Predictable To Witness Sustainable Evolution over 2020-2030 - 3rd Watch News

Read More...

Akouos raises $213m in its IPO, gains nearly 30 percent on first day of trading – BetaBoston

June 26th, 2020 4:48 pm

A Boston biotech trying to develop the first gene therapy to treat hearing loss raised $213 million Friday as it made its stock market debut, 70 percent more than the firm had projected four days ago.

Akouos sold 12.5 million shares at $17, above the original range of $14 to $16, and in line with the upsized share offering and price it filed Thursday morning. On Monday, the company said in a filing with the Securities and Exchange Commission that it hoped to raise $125 million in the initial public offering.

Shares in the company, which is listed on the Nasdaq under the symbol AKUS, closed Friday at $22, up more than 29 percent.

Akouos is the latest biotech to see higher than expected demand in the public markets despite the pandemic-related recession: the 2020 biotech IPO class is averaging a return of 80 percent, according to Renaissance Capital, a pre-IPO research provider for institutional investors.

Some analysts say COVID-19 has underscored the promise of biotechnology to address deadly health threats, generating investor enthusiasm. Among the biotechs whose market values have soared during the epidemic is Moderna, a Cambridge drug company that was the first to get an experimental coronavirus vaccine into human trials. Moderna, which went public in 2018, has a market value of more than $22 billion, though it has no approved products.

Akouos, founded in 2016, is trying to develop the first gene therapy to treat hearing loss in particular, a form of deafness caused by mutations in a single gene. Gene-based hearing loss afflicts 300,000 people in the United States each year, including more than 4,000 newborns.

Its lead candidate is a treatment for a type of genetic hearing loss that afflicts about 7,000 people. The company hopes to use a small virus called adeno-associated virus, or AAV, as a vector to deliver DNA that encodes a functioning gene in target cells. These viruses dont typically cause disease and can be customized to treat different inherited conditions.

Akouos has partnerships with Massachusetts Eye and Ear and Lonza, a Swiss multinational manufacturer that has contracts with drugmakers.

Jonathan Saltzman can be reached at jonathan.saltzman@globe.com

The rest is here:
Akouos raises $213m in its IPO, gains nearly 30 percent on first day of trading - BetaBoston

Read More...

Cell Therapy For Solid Tumors – Contract Pharma

June 26th, 2020 4:48 pm

Base editing, a new player in the gene editing arena, could have an important role in the development of immune-based cell therapies to treat solid tumors. Using cell therapies, such as CAR-T cells, in solid tumors remains challenging: the current word on the street is that such chimeric antigen receptors (CARs) will need multiple gene modifications to make them efficient and it is in this space that base editing could have a substantial advantage.Immune-cell-based therapy is an exciting cell therapy approach to treat cancer where the natural defenses of a patients immune system are used to target and kill cancer cells. Hopes were high following the initial FDA approvals of the first autologous CAR-T therapies for Novartis KYMRIAH (Aug 2017) and Gilead/Kite Pharmas YESCARTA (Oct 2017), both for blood-based cancers, but translating these successes into solid tumors remains a challenge. This is a consequence of the complexity and heterogeneity of solid tumors together with the immune inhibitory nature of the tumor microenvironment.For T cell-based therapies to work, the patient is treated with modified T cells that are rendered capable of identifying and killing tumor cells and, through this, generating a wider immune response against the tumor. Two key approaches used to modify T cells are through expressing a T cell receptor (TCR) known to target the tumor cell or a CAR. Other approaches include using and/or modifying natural killer cells, gamma delta cells or tumor infiltrating lymphocytes. It is not clear which approach will provide the most effective treatment option and in fact it might be that each tumor type responds better to one approach or to a combination of approaches. Irrespective of the approach, it is clear that the current therapies all face similar challenges; the risk of graft vs host disease (GvHD), a lack of durable remissions, on-target or off-target toxicity and cytokine release syndrome.Another layer of complexity for T cell-based therapies lies with the source of T cellsusing the patients own (autologous T cells), or a donor or iPSC-derived T cells (allogeneic). Each approach has advantages and challenges. Briefly, autologous treatments are attractive because they mitigate the risk of immune rejection and GvHD when infused back into the patient. However, they require a complex manufacturing process that necessitates specialist equipment local to the patient to enable the isolation of their T cells followed by rapid manufacture to transform them into engineered T cells ready to infuse back into the patient. At all points during this manufacturing pipeline, the product must be kept sterile and tracible to ensure the correct cells are transfused back into the correct patient. The allogeneic T cells approach is appealing because of the possibility that these could be engineered to be universal donor cells (suitable for all or most patients). Such cells can be manufactured in bulk and administered to multiple patients all over the world. This bulk manufacturing would attract cost-savings once a critical mass of therapy is reached. It could also allow for engineered T cells to be available on-tap to any patient, a game-changer for particular patients whose own T cell count is either too low for engineering, or that transduce poorly with the engineered construct during manufacture. The challenge for allogeneic T cell therapies is the ability to generate cloaked T cells that do not provoke an immune-response in the patient, as this could kill the engineered T cells after transplantation such that they have no efficacy or potentially lead to the death of the patient as a result of a disseminated cytokine storm. Despite these challenges, in April 2019 the US Food and Drug Administration (FDA) approved the first allogeneic CAR-T for investigational use in patients with multiple myeloma and more are expected to follow.To try and achieve a stealth allogeneic T cell that flies under the radar of the patients immune system, genetic engineering is key. Although T cells can be engineered to express a specific TCR or CAR, additional genetic changes are required to provide a cloak of invisibility, prolong the survival of the cells in the patient and enable them to function in an immune suppressive tumor microenvironment. From a simplistic point of view, one could view the modified CAR or TCR as a sat nav, with the T cell being the engine. You need both to get to your destination and, if youre able to improve your engine, its possible the outcome could be achieved faster and in a more reliable fashion. There are several gene knockouts or gene knockdowns that are seen as a natural first step to improving the properties of engineered allogeneic T cells and these are summarized in the table below:As there are multiple gene knockout options, a gene engineering technology capable of making multiple gene edits with as few off-target effects as possible is needed. Indeed, it is conceivable that an effective allogeneic T cell-based therapy might require ten or more gene edits.This prompts the question What is the best gene editing platform or technology to support multiple gene edits? On the surface of it, and owing to its phenomenal adoption in research labs worldwide over the past decade, most currently use the gene editing approach provided by CRISPR-Cas9. CRISPR was first commercialized in 2012 and quite staggeringly made its debut in a clinical trial for cell therapy in June 2016. Although CRISPR is an efficient gene editing tool, its mode of action of generating double-strand breaks in the DNA could be a source of concern. DNA double-strand breaks, which tend to be repaired by the cells repair machinery in an error prone fashion, can cause unintended changes in the genome of engineered cells. Although there are methods for minimizing these off-target effects when single genes are targeted, targeting multiple genes in one cell all at the same time could lead to genome-altering insertions, deletions and/or chromosomal translocations. The impact of this on a patient could be that the cell therapy is effective but the off-target genetic changes lead to deleterious side-effects, impacting patient recovery and potentially survival. Well-known alternatives to CRISPR include transcription activator-like effector nucleases (TALENS) and zinc finger nucleases (ZFN). These approaches have slightly different safety profiles to CRISPR and while optimized for single gene edits or knockouts, multiple gene knockouts still present a challenge for these technologies. Freedom to operate using these technologies in the therapeutics space can also be challenging, particularly for start-up and biotech companies.The potential deleterious impact of off-target effects, particularly for multiple gene edits has opened the door to a newcomer on the gene engineering scene: base editing. This technology first gained prominence from peer-reviewed papers published by researchers from Harvard University.1 Others, such as Rutgers University, have also developed base editing platforms.2 In brief, base editing uses a deaminase enzyme to make a specific base pair change in the DNA. The base pair alteration can either be an A to G or a C to T depending on which deaminase is used. Importantly, the CRISPR-Cas system is used to guide the deaminase to the base pair that is going to be altered, but in this version of CRISPR-Cas, a DNA double-strand break is not made, meaning that the off-target effects with base editing in terms of insertions, deletions or translocations should be substantially reduced.On the surface, this crucial characteristic makes base editing an excellent choice of gene editor for cell therapyit can be used to specifically knock-out multiple genes through the introduction of stop codons or splice site disruptions with limited capacity to introduce substantial, large-scale chromosomal abnormalities. However, as base editing was first published in May 2016,1 substantial research is required to understand fully the utility of base editing in the therapeutic space and to appreciate its advantages and challenges compared with standard gene editing approaches, such as CRISPR-Cas, TALENs and ZFNs.As is somewhat expected of a fashionable area for scientific research, the gene editing space does not stand-still for very long: Prime editing has followed hot on the heels of base editing. Unlike base editing, which makes changes to specific base pairs in the DNA, prime editing allows changes to be made to a run of base pairs by forcing the cell to use a DNA copying system that exists naturally in cells as part of the DNA repair mechanism. Initial data suggest3 that prime editing has higher off-target effects compared with base editing, in terms of introducing insertions and deletions, and more work is needed to understand the comparison and utility of base editing vs. prime editing. It will be interesting to see how prime editing evolves over the months and years within the cell and gene therapy space.Although cell therapy has demonstrated its potential for driving complete remissions in some patients with hematological cancers, the next big step is to translate these early successes into patients with solid tumors. However, due to the complexity of solid tumors, this is not a simple or straight-forward process and multiple factors need to be considered. While the sat nav in the form of an engineered TCR or CAR is crucial, the T cell engine could be the natural starting point for improving efficacy in patients with solid tumors, as could the use of allogeneic rather than autologous approaches. The multiple edits that will be needed to deliver a stealth, engineered, allogeneic off-the-shelf T cell are only now being investigated in earnest and it could be that the new kid on the block, base editing, provides a compelling route forward.References1. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. and Liu, D.R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420424. Doi:10.1038/nature179462. Horizon Discovery to provide access to novel base editing technology, January 2020;https://horizondiscovery.com/en/news/2020/Horizon-Discovery-to-provide-access-to-novel-base-editing-technology (accessed May 2020)3. Anzalone, A.V., Randolph, P.B., Davis, J.R., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149157. doi:10.1038/s41586-019-1711-4Dr. Jonathan Frampton is a business development professional who has been working for Horizon Discovery for the past 9 years and currently as their Corporate Development Partner. He is always scouting for exciting novel technology that could complement Horizons already extensive gene engineering toolkit. In addition to this he works closely with Horizons partners to manage out-licensing opportunities.

See the rest here:
Cell Therapy For Solid Tumors - Contract Pharma

Read More...

Sarepta Addressing Gene Therapy Issue With Two Acquisitions – GuruFocus.com

June 26th, 2020 4:48 pm

On the heels of research deals with two small biotechs, shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) hit their all-time high of more than $172 on June 23.

The share price of the Cambridge, Massachusetts-based biopharmaceutical company has doubled since mid-March. It has a market cap of more than $13 billion.

Sarepta has made a host of deals in the past several years that have made gene therapy a key part of its business, which had been dominated by drugs for muscular dystrophy. One of those pacts, with Roche (RHHBY), could be worth more than $3 billion.

Sarepta currently has a half dozen gene therapies in clinical trials, with another six waiting in the wings, according to BioPharma Dive. One of the companys compounds has shown promise in treating a type of muscular dystrophy, a genetic disease that causes weakness and wasting of the muscles in the arms and legs.

A major challenge of gene therapy is immune system reactions. Sarepta, like other developers, uses a type of virus in its therapy that, while effective, may not be able to given more than once because patients can create antibodies to it.

Thats a problem Sarepta is trying to address in its latest deals with privately held Codiak Biosciences and Selecta Biosciences Inc. (NASDAQ:SELB). In both cases, Sarepta has an option to license the biotechs' technology to develop and commercialize its therapies.

The Selecta deal focuses on gene therapies for Duchene muscular dystrophy and certain limb-girdle muscular dystrophies.

A Zion Market Research report said the global demand for the Duchenne muscular mystrophy therapeutics market was valued at approximately $2.4 billion in 2018 and is expected to grow to more than $20 billion by the end of 2025, a compound annual growth rate of more than 36% between 2019 and 2025.

Given the size of the opportunity, its no surprise Sarepta has plenty of competitors vying for a share of the business, including Pfizer Inc. (NYSE:PFE), PTC Therapeutics (NASDAQ:PTCT), FirbroGen Inc. (NASDAQ:FGEN), Roche and Bristol-Myers Squibb Co. (NYSE:BMY).

The two-year deal with Codiak gives Sarepta the right to license its technology for up to five neuromuscular diseases. If Sarepta exercises an option, Codiak will then handle research until right before the candidate goes into human testing. Sarepta will then be responsible for clinical development and commercializing the drug.

In April, the company announced it has resurrected its antiviral program in response to Covid-19. It has a therapy that is meant to block the coronavirus ability to replicate. The treatment will be tested at the U.S. Army Medical Research Institute of Infectious Diseases.

If it works, it will reduce the ability of the virus to replicate and its ability to infect other cells, Sarepta CEO Doug Ingram told Forbes. He cautioned that the drug is at an early stage.

According to CNN Money, the 21 analysts offering 12-month price forecasts for Sarepta have a median target of $192, with a high estimate of $260 and a low $152. The stock is rated a buy.

Disclosure: The author hold positions in Pfizer and Bristol-Myers Squibb.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

Barry Cohen

He has contributed to a number of financial websites, writing primarily about the stocks of health care companies.

Read more here:
Sarepta Addressing Gene Therapy Issue With Two Acquisitions - GuruFocus.com

Read More...

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer…

June 26th, 2020 4:48 pm

Tom Farrell didnt have much to do after Bellicum announced in January 2017 that they were bringing in a new CEO. He had led the CAR-T company for over a decade, since before Carl Junes New England Journal of Medicinepaper had made cell therapy the hottest thing in cancer research. Now he was facing an 18-month non-compete.

So he worked quickly when, not long after that clock expired in 2018, a banker who helped take Bellicum public told him about a South Korean company called Green Cross LabCell that had built a natural killer cell factory and was looking to develop therapies off it. Farrell hopped a plane to Seoul.

It was hugely impressive, Farrell told Endpoints News.There was nothing [else] I came across that was truly disruptive from a business model perspective.

A year and a half later, Farrell has his new company. Called Artiva, it launches with $78 million in Series A funding and an exclusive deal with Green Cross to push some of their natural killer cell technology into the clinic. Theyll start with a therapy that combines NKs with an approved antibody therapy like rituximab to improve the antibodys effectiveness. Behind that, theyre working on CAR-NK therapy and, longer term, gene-edited CAR-NK cells. RA Capital Management, venBio and 5AM Ventures led the round.

Artiva joins what, after many years, has recently become a booming field. In February, MD Anderson showed that a Takeda-licensed CAR-NK therapy cleared tumors completely in 7 of 11 non-Hodgkins lymphoma patients. Two months later, J&J gave Fate Therapeutics, one of the earliest biotechs in the field, an up-to $3.1 billion deal for their CAR-NK and CAR-T therapies. The Big Pharmas are joined by a slate of recent upstarts, including Celularity, Nkarta, NantKwest, and Cytovia.

Unlike the other newcomers, Artiva makes virtually no claim on having original science. In fact, Farrell said, biotechs emphasis on novel technologies is part of why cell therapy has advanced only incrementally since the approval of the first two CAR-T therapies. Industry hasnt focused enough on addressing the manufacturing issues that have made therapies so costly and difficult to scale, he said.

Lewis Lanier, an immunologist at the University of California, San Francisco and an early pioneer in NK cell research, said Artiva would still face the same questions other drug developers face will some patient reject the cells? Will the natural killer cells actually last a significant amount of time after infusion? but the collaboration could give them an edge.

The Korean Green Cross manufacturing facility is really first rate, thats where the advantage is, Lanier, who is not involved in Artiva, told Endpoints. The science is really routine, theyre not doing anything particularly innovative.

For years, NK cells have been viewed as one of the key potential ways of making off-the-shelf cell therapy. Part of the innate immune system, implanting these cells from donors doesnt lead to the same resistance that donor T cells can. One of the problems, though, is that NKs are finicky, as Lanier puts it, vastly more difficult to grow and manipulate in a lab. Only recently have a couple companies figured out ways to do it consistently. Fate, for instance, uses master lines of iPSC stem cells.

At the Green Cross facility Farrell toured two Novembers ago, the South Korean company had refined a process to derive NK cells from donated umbilical cord blood and cryo-preserve it. A week after his tour, Farrell flew to San Diego for the ASH conference, where he ran into Pete Flynn, another longtime biotech executive out of a job. Flynn had run early development for Fate in its early years before leaving to run R&D for the anti-obesity company Orexigen, which had just gone bankrupt.

Farrell explained what he saw in Seoul and the two debated different approaches to off-the-shelf therapy. They figured the manufacturing base could be a launching pad.

Even though were a Series A company, were looking to become the go-to NK cell, Flynn, now COO, told Endpoints. Basically all the pieces are in place already, whereas for some of those other companies, there might still be some work to do.

Read more here:
Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer...

Read More...

Hemophilia Gene Therapy Market Overview on Demanding Applications 2028 – The Cloud Tribune

June 26th, 2020 4:48 pm

Global Hemophilia Gene Therapy market report from Fact.MRs viewpoint

Fact.MR analyzes the Hemophilia Gene Therapy market from a global as well as local perspective in its recent business intelligence study. The Hemophilia Gene Therapy market reached ~US$ xx Mn/Bn in2019, up by xx% from2018. Further, the report suggests that the Hemophilia Gene Therapy market is anticipated to reach ~US$ xx Mn/Bn in2029with a CAGR of xx% over the forecast period2019-2029.

Queries addressed in the Hemophilia Gene Therapy market report:

Request Sample Report @https://www.factmr.co/connectus/sample?flag=S&rep_id=3107

Competitive landscape

Request Methodology On This Report @https://www.factmr.co/connectus/sample?flag=RM&rep_id=3107

The Hemophilia Gene Therapy market report further scrutinizes the regional analysis into important countries alongwith the market share as well as adoption pattern in each country. Key countries include, country 1, country 2, and country 3, among others.

Key findings of the Hemophilia Gene Therapy market study:

The Hemophilia Gene Therapy report considers2018as the base year and20192029as the forecast period to demonstrate the overall market growth.

Ask analyst about this report athttps://www.factmr.com/report/3107/hemophilia-gene-therapy-market

Why choose Fact.MR?

About Fact.MR

Fact.MR is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. Fact.MRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Continued here:
Hemophilia Gene Therapy Market Overview on Demanding Applications 2028 - The Cloud Tribune

Read More...

Page 481«..1020..480481482483..490500..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick